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Unusual presentation of more common disease/injury

Case report
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SUMMARY
A 34-year-old male presented to the endocrinology
clinic with the complaint of the absence of facial,
axillary and pubic hairs. Further history revealed absent
ejaculations and decreased early morning erections. The
patient had no history of headaches, visual problems or
anosmia. On physical examination, there were sparse
facial, axillary and pubic hairs, bilateral gynaecomastia,
stretch penile length of 5 cm and bilateral testicular
volume of 10 mL. Laboratory investigations showed
low luteinising hormone, follicular stimulating hormone
and testosterone with normal prolactin and thyroid
profile. MRI of the pituitary gland showed no evidence of
pituitary microadenoma or macroadenoma. The patient
was started on testosterone injections. After 9 months
of testosterone replacement, the patient’s testicular
size increased to 20 mL bilaterally and his penile length
increased to the mean adult size for his age with normal
testosterone and luteinising hormone. He was, thus,
advised to discontinue testosterone therapy.
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Hypogonadotropic hypogonadism (HH) is a relatively uncommon disorder with prevalence ranging
from 1 in 10 000 to 1 in 86 000 individuals and
a male to female ratio of 1:5.1 2 Idiopathic HH is
diagnosed in the presence of low testosterone and
follicular stimulating hormone/luteinising hormone
without any structural or functional abnormalities
in the hypothalamic–pituitary–gonadal (HPG) axis.
It is primarily due to a flaw in the secretion or action
of gonadotropin-releasing hormone (GnRH) and is
diagnosed when there is a failure of sexual maturation by 18 years of age.2
Typically, puberty is caused by the maturation
of the HPG axis during which the pulsatile release
of GnRH by the hypothalamus causes secretion
of luteinising hormone and follicular stimulating
hormone by the pituitary gland. In males, this
causes the production of testosterone and the maturation of sperm.3 This results in the development
of secondary sexual characteristics and attainment
of fertility. Generally, puberty in boys starts around
11 years of age and is complete by the age of 16–17
years. Delayed puberty for boys is defined as the
absence of testicular enlargement by an age 2–2.5
SD above the mean for a given population (usually
14 years of age).4 5
Both congenital and acquired forms of HH are
present with the latter caused by chemotherapy, radiation, damage to the pituitary gland/hypothalamus,

malnutrition and hyperprolactinaemia among other
reasons. Treatment of this condition is paramount
because it leads to a significantly decreased quality
of life and problems such as reduced muscle mass,
energy, libido, facial and pubic hair, small genitalia,
failure of voice to deepen, infertility, etc. Furthermore, patients might also develop low self-esteem,
depression and osteoporosis later in life because of
low testosterone levels in the body.6

Case presentation
A 34-year-old male with no known co-morbids presented to the endocrine clinic with the
complaints of scarce facial, axillary and pubic
hairs. The prompting factor for the patient to seek
medical advice was that he wanted to get married
soon. Further history revealed absent ejaculations
and decreased early morning erections. There was
no current or prior history of headache, visual problems, decreased sense of smell, trauma or radiation
exposure. The patient was not using any medication
or hormone therapy and had a sedentary lifestyle.
Past medical, surgical and family history was unremarkable.
On examination, the patient had a blood pressure
of 116/70 mm Hg, pulse of 92 beats per minute,
height of 172.5 cm and a weight of 68 kg. There
were no facial hairs, sparse axillary and pubic hairs,
bilateral gynaecomastia, stretch penile length of 5
cm and bilateral testicular volume of 10 mL. The
rest of the physical examination was unremarkable. A diagnosis of hypogonadism was made and
he was advised to have serum luteinising hormone,
follicular stimulating hormone, testosterone (AM),
prolactin, thyroid -stimulating hormone and free
thyroxine tested.

Investigations
The laboratory reports of the patient showed
luteinising hormone 2.60 mlU/mL (normal limit
in males: 1.2–7.8), follicular stimulating hormone
1.50 mlU/mL (normal limit in males: 1.5–15.4),
ante meridiem (AM) testosterone 55.99 ng/dL
(normal limit in males: 249–836), prolactin 5.2 ng/
mL (normal limit in males 2–18 ng/mL), thyroid
stimulating hormone 1.03 ulU/mL (normal limit:
0.4–4.2) and free thyroxine 1.13 ng/dL (normal
limit: 0.89–1.76).
After biochemical confirmation of HH, he was
advised MRI of the pituitary gland which showed
a normal pituitary fossa with no evidence of pituitary microadenoma or macroadenoma (figure 1).
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Table 2

Follow-up laboratory investigations of the patient

Investigation

Value

Normal limit

Luteinising hormone (mlU/mL)

3.30

1.2–7.8

Testosterone (AM) (ng/dL) (on
replacement)

643.3

249–836

Testosterone (AM) (ng/dL) (off
replacement)

433.8

249–836

AM, ante meridiem.

Discussion

Figure 1 MRI of the pituitary gland showing no pituitary
pathology. HPR, half-plane representation; LP, left posterior; MRI axis:
RA, right anterior.
The patient was subsequently started on testosterone injections.
Table 1 shows the initial laboratory investigations of our patient.

Differential diagnosis

Hypogonadotropic hypogonadism.

Treatment

The patient was started on testosterone injection 250 mg once
every 4 weeks which was later decreased to 250 mg once every
6 weeks. At that time, the plan was to start the patient on pulsatile
GnRH therapy once he got married in order to restore fertility.

Outcome and follow-up

At 3 months on follow-up, the morning testosterone peak level
of the patient reached 643.3 ng/dL with trough level of 163.3 ng/
dL. After 9 months of testosterone replacement, the patient’s
testicular size increased to 20 mL bilaterally and his penis length
increased to the mean adult size for his age. He became well
virilised. Considering the sexual maturation on clinical examination, patient was advised to hold testosterone replacement and
his testosterone and luteinising hormone levels were rechecked
after 2 months to see whether the hypothalamic–gonadal axis
had recovered. His testosterone levels off replacement were
433.8 ng/dL with a luteinising hormone level of 3.30 mlU/mL
(1.2–7.8). The patient was, therefore, advised to stop testosterone. Table 2 shows the follow-up laboratory investigations of
our patient.
Table 1

Initial laboratory investigations of the patient

Investigation

Value

Normal limit

Luteinising hormone (mlU/mL)

2.60

1.2–7.8

Follicular stimulating hormone (mlU/mL)

1.50

1.5–15.4

55.99

249–836

Testosterone (AM) (ng/dL)
Prolactin (ng/dL)

5.2

2–18

Thyroid-stimulating hormone (ulU/mL)

1.03

0.4–4.2

Free thyroxine (ng/dL)

1.13

0.89–1.76

2

Multiple factors may have been involved in causing the patient’s
hypogonadism; however, a detailed history and examination
failed to suggest alternative reasons for it. Our patient presented
at the age of 34 years which is quite unusual; however, Sumko et
al7 described a similar case of a 27-year-old man who was found
to have microphallus, undescended testes and scarce pubic hair,
whereas Zhang et al8 reported a 34-year-old male with osteoporosis, diabetes mellitus and metabolic syndrome. Both of these
patients were discovered to have idiopathic HH while being
evaluated for another disease. This hesitancy to seek medical
care regarding delayed puberty may be because of the social
stigma associated with sexual disorders; therefore, a lot of the
cases might go unreported and present at a relatively advanced
age. Our patient was 34 years old at presentation; therefore,
the possibility of constitutionally delayed puberty was remote.
However, at younger ages, it may be difficult to distinguish
between constitutionally delayed puberty and HH. Two clinical
features that might help to differentiate between the two are
undescended testes and micropenis, which are more frequently
found in HH.7
Failure of pulsatile GnRH secretion may be due to mutations
in a number of genes such as PROK-2, FGFR1, etc. Furthermore, a protein, prokineticin-1, is involved in olfactory bulb
development and release of GnRH. Mutations in this protein
can also cause idiopathic HH which may be normosmic or
anosmic (Kallmans syndrome).7 Although many genes have been
linked with idiopathic hypogonadotropic hypogonadism (IHH),
the majority of cases are due to genetic mutations which are yet
unidentified.
Treatment of this disorder mainly depends on the desire for
fertility. Androgen replacement alone can be used to reverse the
problems associated with hypogonadism and is considerably less
expensive than the other options available. Furthermore, our
patient did not desire fertility at the time of presentation and
considering the cost this was the best choice for him. However,
pulsatile GnRH therapy and gonadotropins are better suited
for patients who wish to become fertile because in addition to
treating the low testosterone state they also stimulate spermatogenesis.6
Previously, treatment was thought to be lifelong; however,
Raivio et al2 described 15 patients who had sustained reversal
of HH on discontinuation of therapy. Reversals occurred in
five men treated with testosterone alone, three men treated
with pulsatile GnRH therapy only and seven men who received
a mixed regimen, including testosterone, gonadotropins or
GnRH. Although the mechanism of reversal is unclear, the
researchers speculated that because sex steroids were the only
common medication given to all the patients with reversal,
they somehow modify the hypothalamic neurons responsible for producing GnRH. This might lead to reversal of
HH and initiation of spermatogenesis. After the administration of testosterone, our patient’s HPG axis recovered with
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subsequent sexual maturation on clinical examination; therefore, he was advised to stop testosterone injections.
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►► Hypogonadism has significant psychosocial and health-
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related effects which are easily treatable if this condition is
caught early.
►► Treatment depends on the desire for fertility and can be via
testosterone replacement, pulsatile gonadotropin-releasing
hormone therapy or gonadotropins.
►► In a patient with hypogonadotropic hypogonadism being
treated with testosterone, treatment should be temporarily
discontinued after sexual maturation has occurred because a
minority of cases may have achieved reversal.
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